CD4 and diffuse large B-cell lymphoma: In another cohort of 41 patients with DLBCL treated with CAR-T cells (axicabtagene ciloleucel), only 40% of patients had detectable CD19+ B lymphocytes after 12 months, and 50% of patients had a CD4+ cell count <200 cells/μL after 18 months following infusion.